Yonsei University School of Medicine and Milner Therapeutics Institute of Cambridge University held an online symposium called “AI Medicine and Novel Drug Target Discovery,” from Feb. 22-24. 

According to Yonsei, the symposium invited 10 new drug development experts from Korea and the United Kingdom and discussed the current status and prospects of developing treatments using artificial intelligence with the attendance of more than 450 people. 

The participants discussed how AI is being introduced in finding target proteins and deriving candidate substances for treatment in the early stage of new drug development. AI-based clinical trials and pharmacovigilance cases were also presented, examining AI’s role from various aspects. 

“We have taken the first step toward upgrading the next generation of new drugs through academic communication and exchange of research results between Korea and the U.K.,” Professor Cheong Jae-ho at Yonsei University said. “We hope that the event will serve as an opportunity to promote scientific and technological exchanges and cooperate in developing new drugs to solve human diseases and improve health.”

Professor Park Yu-rang of the Department of Medical Life Systems Information System delivered a lecture on AI models' development. She discussed the related side effects of immuno-oncology based on the hospital information system’s data.